CORAL SPRINGS, FL--(Marketwired - January 20, 2015) - Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have added Keith Gordon, DVM as their first Veterinarian to join the Company's Medical Advisory Board. The addition of Dr. Gordon comes just a few weeks after the successful launch of Nutra Pharma's newest product, Pet Pain-Away for the treatment of chronic pain in companion animals.
"We are thrilled to announce the addition of Dr. Gordon to our Medical Advisory Board," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "We began shipping Pet Pain-Away just a few weeks ago and have already received positive responses from hundreds of product users as well as several Veterinarians," he continued. "With the success that we are already seeing with Pet Pain-Away, it behooves us to have a Veterinarian of Dr. Gordon's caliber on our Advisory Board to help steer the future course of Nutra Pharma's animal health product line," he concluded.
Dr. Keith Gordon has been practicing Veterinary Medicine for thirty years. For twenty three years, he owned his own practice, All Pets Animal Hospital in Staten Island, NY before merging with a newer state of the art facility, Bay St Animal Hospital where he currently practices. Dr. Gordon also started and runs a veterinary business called House Calls for Pets. He has always had an interest in treating arthritic animals and in 2009 was certified to perform Stem Cell Regenerative Medicine.
"I am excited to join the Medical Advisory Board of Nutra Pharma and support their efforts with Pet Pain-Away," commented Dr. Keith Gordon. "This new product provides another mode of treatment for pets with chronic pain that have not responded well to other therapies such as narcotics, NSAIDS, or steroids; and seems to lack the side-effects associated with all of those other modalities," he continued. "I've already received results from the Pet Pain-Away in six patients. Two people used the word 'miracle' and all but one had significant improvement with their pain management. It's really exciting to have an alternative product to try to make our buddies more comfortable," he concluded.
Pet Pain-Away is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever. The product is primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs, cats and horses. Specialized proteins in Pet Pain-Away block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off.
According to The American Pet Products Association (APPA) there are 83 million dogs and 95 million cats in the US. These companion animals are as susceptible as humans to ailments that require pain-relieving solutions. The total market for companion animals in the US reached an estimated $58.5 billion in 2014. Of these expenditures, over $13 billion was spent on medication for the animals. Additionally, a 2009 survey conducted by Virbac Pharmaceuticals puts the annual US market for companion animal pain relievers at more than $250 million.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The addition of Dr. Keith Gordon to the Medical Advisory Board should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Nutra Pharma Corp.